STOCKS TELEGRAPH

Tag: NASD:MIRA

  • Stock Soars For MIRA Pharmaceuticals After Major Neuropathic Pain Study

    Stock Soars For MIRA Pharmaceuticals After Major Neuropathic Pain Study

    The stock price of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has increased significantly, with shares rising 19.45% to $2.21 in the current market. This growing trend confirms MIRA’s status as a pioneer in cutting-edge medicines and comes after the release of a ground-breaking finding in the management of neuropathic pain.

    MIRA Pharmaceuticals’ Highlights Breakthrough Efficacy

    In a recent pre-clinical study conducted on rats, MIRA Pharmaceuticals unveiled that its novel oral ketamine analog, Ketamir-2, exhibited remarkable efficacy in reversing neuropathic pain. Utilizing a nerve ligation model at Pharmaseed Ltd, the study sought to mimic human neuropathic pain and focused specifically on mechanical allodynia.

    The results were compelling: Ketamir-2 not only reduced pain significantly at low doses but also achieved complete normalization of pain thresholds at higher doses, marking a 100% reversal of the neuropathic pain signal. This finding is particularly significant when contrasted with traditional oral ketamine, which failed to deliver similar results under the same conditions.

    Future Studies and Potential Implications

    Encouraged by these promising results, MIRA Pharmaceuticals is advancing its research to assess Ketamir-2’s potential in treating other conditions, including cancer-induced depression and neuropathic pain. With the potential to show efficacy in human trials as early as 2025, the business is confident that these investigations might result in quicker regulatory approvals and creative clinical research designs.

    MIRA Revolutionizing the Standard of Care for Neuropathic Pain

    The successful development of ketamir-2 represents a significant advancement for both MIRA Pharmaceuticals and the broader field of neurologic and neuropsychiatric drug research. Many patients have considerable reductions in quality of life due to neuropathic pain, which has historically been linked to few and frequently ineffective therapeutic choices.

    The research conducted by MIRA Pharmaceuticals indicates that Ketamir-2 may provide a safer, more readily available, and more efficacious substitute, which has the potential to revolutionize the current standard of treatment. Moreover, the ability to administer Ketamir-2 orally without the severe psychotropic side effects typically associated with ketamine underscores its potential as a pioneering treatment, offering renewed hope to patients with few therapeutic options.

  • What Helped MIRA Pharmaceuticals Recover In Extended Session

    What Helped MIRA Pharmaceuticals Recover In Extended Session

    MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) witnessed a notable upswing of 7.04% in its stock value, reaching $3.42 during the extended trading session on Wednesday. This surge contributed to the partial recovery of MIRA Pharmaceuticals stock, mitigating an 18.08% loss in the regular session and concluding at $3.20. The impetus for this positive momentum was an announcement by MIRA Pharmaceuticals heralding a paradigm shift.

    In a groundbreaking revelation, MIRA Pharmaceuticals (MIRA) disclosed pioneering insights into the cognitive enhancement effects of MIRA1a in normal mice. This unveiling occurred during a presentation at the Grand Rounds of the University of Louisville’s Christine Lee Brown Envirome Institute. This significant finding was delivered by Dr. Adam Kaplin, MD, PhD, President and Chief Scientific Officer at MIRA Pharmaceuticals. He is also an Adjunct Faculty member at Johns Hopkins School of Medicine.

    His presentation focused on the unique properties of THC and MIRA1a, an innovative analog of THC, which were the focus of Dr. Kaplin’s research on psychotropic drug development. The research highlighted that while THC displayed a biphasic response, being therapeutic at low doses but toxic at high doses, MIRA1a exhibited remarkable stability, even at elevated doses, without inducing any toxic side effects.

    Moreover, MIRA1a demonstrated a twofold increase in the performance of normal adult mice in learning and memory tests, underscoring its potential to enhance cognitive abilities beyond conventional thresholds. The revelation of MIRA1a’s profound cognitive enhancement, evident even after a single dose, signifies a transformative breakthrough in neuropsychiatric research.

    This landmark discovery solidifies MIRA Pharmaceuticals’ position at the forefront of innovative developments in psychotropic drug research. With an unwavering commitment to seizing industry-defining opportunities, MIRA Pharmaceuticals stands poised to capitalize on a vast market potential. The company concentrates its efforts on addressing anxiety and neuropathic pain within the expansive traditional neurological markets valued at over $90 billion.

    According to Dr. Kaplin, cognitive impairment can be treated in a revolutionary way, especially in the early stages of dementia, according to his findings. MIRA1a has consistent therapeutic effects, even at high doses, making it a promising candidate to treat neuropsychiatric disorders.